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Two regulatory pathways, bone morphogenetic protein
(BMP)/transforming growth factor- (TGF) and the transcrip-
tion factor RUNX2, are required for bone formation in vivo.
Here we show the interdependent requirement of these path-
ways to induce an osteogenic program. A panel of Runx2 dele-
tion and point mutants was used to examine RUNX2-SMAD
protein-protein interaction and the biological consequences on
BMP2-induced osteogenic signaling determined in Runx2 null
cells. These cells do not respond to BMP2 signal in the absence
of Runx2. We established that a triple mutation in the C-termi-
nal domain of RUNX2, HTY (426–428), disrupts the RUNX2-
SMAD interaction, is deficient in its ability to integrate the
BMP2/TGF signal on promoter reporter assays, and is only
marginally functional in promoting early stages of osteoblast
differentiation. Furthermore, the HTY mutation overlaps the
unique nuclear matrix targeting signal of Runx factors and
exhibits reduced subnuclear targeting. Thus, formation of a
RUNX2-SMAD osteogenic complex and subnuclear targeting
are structurally and functionally inseparable. Our results estab-
lish the critical residues of RUNX2 for execution and comple-
tion of BMP2 signaling for osteoblastogenesis through a mech-
anism that requires RUNX2-SMAD transcriptional activity.
Skeletal development and bone formation require coordi-
nated activities of multiple signaling pathways that include
bone morphogenetic protein 2 (BMP2)5 and transforming
growth factor- (TGF). Transduction of these signals results
in the activation of target genes that are essential for bone
development. Specific receptor-regulated SMADs (R-SMADs)
serve as substrates for the BMP and TGF/activin/Nodal
receptors. SMAD-1, -2, -3, and -5 transduce, whereas Smad-4
serves as a common partner for all R-SMADs to provide the
DNA binding property (1, 2). The structural and functional
domains of SMADproteins are well characterized with binding
sites for SMAD ubiquitination-related factor (SMURF) ubiq-
uitin ligases, and phosphorylation sites for several classes of
protein kinases (3). The MH2 domain mediates interactions
with transcriptional activators and repressors for signal trans-
duction; including co-regulators of skeletal development (4–7).
Several studies suggest that the principle activity of BMP and
TGF SMADs for the control of skeletogenesis is mediated by
their interaction with RUNX2 (CBFA1/AML3). This runt-re-
lated transcription factor is critical for osteogenic lineage com-
mitment and formation of the skeleton (8–12). Mutations in
the human RUNX2 cause cleidocranial dysplasia (13, 14). Tar-
geted disruption of Runx2 in mice results in the maturational
arrest of osteoblasts and a complete lack of mineralized bone
(15–17). The gene regulatory properties of RUNX factors are
mediated not only by DNA binding to cognate elements, but
also through the formation of selective co-regulatory protein
interactionswith co-activator and co-repressor proteins (9, 10).
The C terminus of RUNX proteins contains a 31-amino acid
nuclear matrix targeting signal (NMTS), an essential well con-
served functional domain, required to direct RUNX to distinct
nuclear matrix-associated sites within the nucleus that support
gene expression (18–20). The tight association of RUNX pro-
teins with the nuclear matrix provides a platform for assembly
of multicomponent regulatory complexes that control both
activation and repression of genes during cell fate determina-
tion and differentiation (9, 21–23). Among the co-regulatory
proteins interacting with the RUNX2C terminus and recruited
toRUNX2 subnuclear domains aremediators of developmental
signals, which include the TGF- and BMP-induced SMADs
(13, 24, 25). The biological significance of the RUNX2 C termi-
nus is revealed by a knock-in mutation in which mice lacking
the C terminus fail to develop a mineralized skeleton (17), con-
firming the importance of this region for in vivo osteogenesis.
Particularly relevant to bone formation, early studies showed
that BMP2-treated Runx2 null cells could not induce the com-
plete osteoblast differentiation program (15, 26, 27). RUNX2
has been shown to interact with SMAD proteins (13, 28–32)
and recruit SMADs to subnuclear sites of active transcription
(24). Deletion mutant studies have identified a RUNX2-SMAD
interacting domain (SMID) in theC terminus (23) that overlaps
the NMTS, but definitive proof that RUNX2-SMAD interac-
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tion is essential for osteoblastogenesis has yet to be established.
Only by disruption of the RUNX2-SMAD interaction in the
context of the entire protein can the hypothesis that RUNX2 is
required to mediate the BMP2 osteogenic signal, be tested.
In these studies, by site-directedmutagenesis, we defined the
specific RUNX2 amino acids required for physical and func-
tional interaction with either BMP- or TGF-responsive
SMADs. Three residues (HTY, 426–428) positioned in the car-
boxyl end of the RUNX2 SMID contribute to the osteogenic
activity of RUNX2, formation of the RUNX2-SMAD complex,
and integration of the BMP/TGF signal. The HTY mutant
RUNX2protein retainsDNAbinding and transcriptional activ-
ity but has impaired subnuclear targeting and no ability to bind
SMADs, thus preventing transduction of a BMP2-mediated
osteogenic function. These findings of minimal amino acid
requirements for bothRUNX2-SMAD interactions and the tar-
geting of a RUNX2-SMAD functional complex to subnuclear
domains provide compelling evidence for a structural coupling
of SMADswith RUNX2 that is essential for execution and com-
pletion of BMP2 osteogenic signal.
EXPERIMENTAL PROCEDURES
Cell Cultures—Human cervical carcinoma HeLa cells were
cultured and maintained as previously described (23). Runx2
null cells were isolated from calvarial tissue of 17.5-day-old
mouse embryos. Cells were maintained in modified Eagle’s
medium (MEM) containing 10% fetal bovine serum, and pen-
icillin G (100 units/ml), and streptomycin (100 g/ml) at 37 °C
in a humidified atmosphere of 5% CO2 in air. Cells were stably
transfected with expression vector of mouse telomerase using
FuGENE 6 regents (Roche Applied Science) and selected
against G418 for 2 weeks. Detailed description andmorpholog-
ical characteristic of the established Runx2 null cell lines are
reported elsewhere (27).
Plasmids and Adenoviral Constructs—The BMP2- and
TGF-responsive FLAG-tagged receptor SMAD (SMAD2 and
3) constructs, and the 3TBRE-Luciferase and 6Runx-Lucif-
erase plasmids are reported previously (23). Expression con-
struct of hemagglutinin (HA)-tagged RUNX2, deletion 391,
Y428A, and R398A&Y428A are described earlier (20, 23).
HA-tagged RUNX2 point mutants H426A, T427A,
HT426, 427AA, FTY405–407AAA, HTY426–428AAA, and
FTYHTY405–407,426–428AAAAAA were generated with a
two-step PCR approach. In the first step two independent but
overlapping PCR products were generated using wild-type
Runx2 cDNA as template. For PCR product 1, the common
forward primer contained an ApaI site, 5-GAACTGGGCCC-
TTTTTCAGACCCCAG-3, whereas the mutant specific
reverse primers were 5-GTGGTGGCAGGTACGTGGCGT-
AGTGAGTG-3 for H426A, 5-GTGGTGGCAGGTACGCG-
TGGTAGTGAGTG-3 for T427A, 5-GTGGTGGCAGGTA-
CGCGGCGTAGTGAGTG-3, for HT426,427AA, 5-GTGG-
TGGCAGTGCCGCGGCGTAGTGAGTG-3 for HTY426–
428AAA, and 5-CTGGCGGGGTTGCTGCAGCGGTGGCT-
GGG-3 for FTY405–407AAA. For PCR product 2, the
mutant-specific forward primers were 5-CACTCACTACGC-
CACGTACCTGCCACCAC-3 for H426A, 5-CACTCACTA-
CCACGCGTACCTGCCACCAC-3 for T427A, 5-CACTCA-
CTACGCCGCGTACCTGCCACCAC-3 for HT426,427AA, 5-
CACTCACTACGCCGCGGCACTGCCACCAC-3 for HTY426-
428AAA, and 5-CCCAGCCACCGCTGCAGCAACCCCGC-
CAG-3 for FTY405–407AAA with the common reverse
primer containing an XhoI site and stop codon, 5-TTTCTC-
GAGTCAATATGGCCG-3. Both PCR products for each
mutant plasmid were purified and combined as template to
generate a full-length PCR product containing the respective
mutation. For the full-length PCR reactions the forward primer
with ApaI site and the reverse primer with XhoI site are the
same as above. The final products carrying the respectivemuta-
tions were sequentially digested with ApaI/XhoI and ligated
into the similarly digested HA-RUNX2 vector. A similar two
step PCR approachwas implied to generate RUNX2 expression
plasmid carrying six alanine mutations (FTYHTY405–
407,426–428AAAAAA). FTY405–407AAA plasmid was used
as template, and the primer pairs are as described above for
HTY426–428AAA. The presence of mutated sequences and
the in-frame ligation of all the plasmids were confirmed by
automated sequencing using an internal primer.
Adenovirus expressing wild-type and C-terminal deletion
mutant (391) of RUNX2 are described previously (23). The
Y428A and HTY426–428AAA mutant RUNX2 adenoviruses
were generated by using the Adenovator system (Qbiogene,
Carlsbad, CA). Briefly, HA-tagged mutant Runx2 cDNA were
amplified by PCR using a common forward primer, 5-CTTG-
GAAGATCTTTACCATGGATCTGTACGACGATGACGA-
TAAG-3, and a common reverse primer, 5-CCTGAAAGATC-
TGCCCTCTAGATCAATATGG-3, containing an engineered
BglII restriction site. PCR products were digested with BglII
enzyme and cloned into similarly digested pAdenoVator-
CMV-IRES-GFP (Qbiogene). Presence of mutation and the
integrity of the reading frame of the positive clone were con-
firmed by automated DNA sequencing. The expression and
transcriptional activity of all pAdeno Vator constructs were
examined inHeLa cells. The plasmidswere then linearizedwith
PmeI digestion and co-transformed into BJ5183 Escherichia
coli cells along with the viral DNA plasmid pAdenoVator E1/
E3. Recombinantswere selected for kanamycin resistance and
screened by restriction enzyme analysis. The recombinant
adenoviral constructs were subsequently cleaved with PacI to
expose its inverted terminal repeats and transfected into QBI-
293A cells to produce viral particles. The virus particles were
recovered from cells by three freeze/thaw cycles and further
amplified. Fourth amplification containing high titer viral par-
ticles was purified by CsCl2 gradient and used for subsequent
infections. The following multiplicity of infections (m.o.i.) was
used for wild-type and point mutants of Runx2 adenovirus to
maintain an equal level of expression and low cytotoxicity in
Runx2 null cells (wild type, 50 m.o.i.; HTY, 60 m.o.i.; Y428A,
70 m.o.i.; and 391, 37 m.o.i.).
Transient Transfection and Luciferase Assays—All transient
transfectionswere performedusing SuperFect transfection rea-
gent (Qiagen Inc). For promoter reporter assays, HeLa cells
plated in 6-well dishes were transfected at 40% confluency with
varying concentrations (250–500 ng) of Runx2 expression vec-
tors, 0.5 g of receptor SMADs, 500 ng of the multimerized
Runx (6xRunx) or 3xTBRE promoter fusedwith luciferase gene,
Runx2-Smad Complexes Integrate BMP2 Signals
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and 100 ng of Renilla luciferase reporter construct. Briefly,
DNA-lipid complexes were formed in serum-free Dulbecco’s
modified Eagle’smediumbymixing the indicatedDNAamount
with 7 l of SuperFect reagent and incubating for 15 min at
room temperature. The complexes were diluted in 1ml of com-
plete Dulbecco’s modified Eagle’s medium and overlaid on pre-
washed cells. After 3 h, DNA-lipid complexes were removed,
washed once with 1 phosphate-buffered saline, fed with fresh
medium, and cultured for an additional 18 h in the presence or
absence of 100 ng/ml BMP2. For TGF-responsive Smads, treat-
mentwithTGF (5 ng/ml)was carried out 6 h prior to harvesting.
Cells were lysed in reporter lysis buffer, and luciferase activity was
determined using a Dual Luciferase Reporter Assay kit (Promega,
Madison,WI).Resultswereobtained fromat least three independ-
ent experiments with triplicate samples.
Adenoviral Infections—Runx2 null cells were plated at a den-
sity of 0.3 106 cells per well of a 6-well plate. Cultures at 70%
confluence were infected with the Runx2 (WT, Y428A, HTY,
and 391) or -galactosidase expressing control adenovirus in
serum-free MEM. After 90 min, cells were washed in MEM
without serum followed by addition of complete MEM. Cells
were cultured in the presence or absence of BMP2 (100 ng/ml)
for an additional 12 days. Two days post infection cells were fed
with osteogenicmedia (MEMcontaining-glycerophosphate
and ascorbic acid). Media were changed every other day, and
cells were subsequently harvested at indicated days for isolation
of RNAor fixed in 2% formaldehyde in cacodylic buffer for ALP
histology.
RNA Isolation and Quantitative PCR Analysis—RNA was
isolated from control and adenovirus-reconstituted Runx2 null
cells at different days of culture in the presence and absence of
BMP2. Cells were briefly washed with phosphate-buffered
saline and lysedwithTRIzol reagent (Invitrogen) to isolate total
RNA according to the manufacturer’s protocol. RNA was
treated with DNase I to remove any DNA contamination and
purified using a DNA-free RNA column kit (Zymo Research,
Orange, CA). SuperScript first strand synthesis kit (Invitrogen)
was used to reverse transcribed 1 g of RNA. cDNA was then
subjected to real-time PCR tomeasure relative transcript levels
using SYBR Green Master Mix (Bio-Rad) and gene-specific
primers. Specificity of primers was initially verified by dissoci-
ation/melting curve for the amplicons. Transcript levels were
normalized to glyceraldehyde-3-phosphate dehydrogenase lev-
els in respective samples. The primers used for amplification
were reported previously (27).
ALP Histology—Cells infected with indicated adenoviruses
and cultured in the presence or absence of BMP2 for 4, 8, and 12
days were washed twice in 0.1 M cacodylic buffer and subse-
quently fixed in 2% formaldehyde in cacodylic buffer for 10min
at room temperature. Afterwashingwith 0.1M cacodylic buffer,
the following reagents all purchased from Sigma-Aldrich were
added for the histological stain: Napthol AS-Mx phosphate
disodium salt (25 mg),N,N-dimethyl formamide (1.4 ml), 0.2 M
Tris maleate buffer (25 ml), and Fast red salt (50 mg). The total
volume was made up to 50ml by the addition of distilled water,
and the solution was filter-sterilized and immediately added to
the wells. The plates were incubated at 37 °C for 30min or until
color development was observed. The wells were then rinsed
with distilled water, and stained cells were visualized using an
inverted microscope.
Immunoprecipitation and Western Blots—HeLa cells were
plated at a density of 0.7  106 cells per 100-mm plates. Cul-
tures at 60% confluence were transfected with 5 g each of
RUNX2 (WT or mutant protein) and SMAD1 or -3 expression
plasmids using SuperFect reagent. BMP2 (100 ng/ml) treat-
ments were carried out 3 h post-transfection, whereas those for
TGF (5 ng/ml) were carried out 6 h before harvesting. Cell
were harvested 20–24 h following transfection in phosphate-
buffered saline containing 25 M proteasome inhibitor MG132
(Sigma-Aldrich) and Complete protease inhibitor mixture
(Roche Applied Science). Cells were lysed by sonication at 10%
for 10 s, and this process was repeated 5 times. Lysates clear of
cellular debris were collected by centrifugation at 3000 rpm for
4min, and 10% of the total lysate was saved as input. Remaining
lysates were combined with 15 g of species matched normal
IgG, rabbit polyclonal Runx2 (M70, Santa Cruz Biotechnology)
or mouse monoclonal FLAG (Sigma-Aldrich) antibody, and
incubated on a rotating wheel for 1 h at 4 °C. Immunoprecipi-
tates were collected with Protein A/G-agarose beads (Santa Cruz
Biotechnology) and washed four times with phosphate-buffered
saline containing 25 M MG132 and protease inhibitor mixture.
Total cell lysatesor immunoprecipitateswere fractionatedbyelec-
trophoresis on a 12% SDS-polyacrylamide gel, transferred onto
Immobilon Pmembranes (Millipore).Western blots were probed
withmonoclonal antibodies against Runx2 and FLAG and visual-
izedwith appropriate horseradish peroxidase-conjugated second-
ary antibody and chemiluminescence.
Isolation of Nuclear Extracts and Electrophoretic Mobility
Shift Assay—HeLa cells plated in 100-mm culture dishes were
transfected with 5 g of wild-type and mutant Runx2 expres-
sion plasmid and pcDNA3.1 as empty vector control. Cells were
harvested 30 h later for isolation of nuclear extracts essentially
as described previously (22). Concentrations of nuclear protein
were determined by Bradford assay, and vials were flash frozen
and stored at75 °C till required. Oligonucleotides represent-
ing a consensus Runx binding site was used for electrophoretic
mobility shift assay and are reported earlier (22). Preparation
and radioactive labeling of the oligonucleotide probe is essen-
tially as described previously (22). Nuclear extracts (10 g)
from wild-type and mutated RUNX2 were incubated with
labeled probe for 20 min at 22 °C and loaded onto a 4% nonde-
naturing polyacrylamide gel. Dried gelswere exposed to film for
autoradiography.
In Situ Immunofluorescence—HeLa cells were plated at a
density of 8  104 cells/well on gelatin-coated coverslips in
6-well culture dishes. Cells at 40% confluency were transfected
with 1g each ofRunx2 (WTormutant), FLAG-tagged BMP2-
responsive Smad1 and cultured for 18 h. BMP2 (100 ng/ml) was
added 3 h post-transfection. Cells were processed for in situ
immunofluorescence as whole cell preparations as described
previously (19). RUNX2 was detected by a rabbit polyclonal
antibody (Santa Cruz Biotechnology) and SMAD with a
mouse monoclonal antibody against FLAG epitope (Sigma-
Aldrich) at a dilution of 1:400 each. Secondary antibodies
used were anti-rabbit Alexa 488 and anti-mouse Alexa 568
(Molecular Probes) at a dilution of 1:800. Images were cap-
Runx2-Smad Complexes Integrate BMP2 Signals
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tured using a Zeis Axioplan microscope interfaced with a
charge-coupled device camera and analyzed with Meta-
Morph software (Universal Imaging Inc).
For analysis of in situ co-localiza-
tion, confocal microscopy was per-
formed. A Leica TCS-SP inverted
confocal microscope equipped with
argon-helium and neon lasers with
specific excitation lines was used
(Bannockburn, IL). Ten randomly
selected cells (five each from two
independent cover slips) with equal
expression levels of both proteins
were used. Cell images with
0.25-msection in respective wave-
length were captured using similar
exposure time. Two-dimensional
progression was obtained, and
numbers of Runx2 and SMAD foci
per nucleus were counted using
Leica Lite 2.0 and MetaMorph
Imaging Software. The percent
overlap was counted from total foci
expressing WT and HTY mutant
proteins. Average numbers of foci
pooled from ten independent cells
that exhibited colocalization are
presented.
RESULTS
Specific Residues within the
SMID/NMTS Domain Define
RUNX2-SMAD Interactions—Stud-
ies were initiated to test the hypoth-
esis that a critical role of RUNX2 in
inducing bone formation and in reg-
ulating the progression of osteoblast
differentiation depends on its inter-
action with SMAD proteins in
response to BMP2 and TGF sig-
naling. We previously documented
by C-terminal deletion studies the
presence of a SMID in RUNX2,
which overlaps the well character-
ized nuclear matrix targeting signal
(NMTS) as illustrated in Fig. 1A.We
first mutated the FTY and HTY res-
idues that form the tips of loops 1
and 2 in the NMTS/SMID, respec-
tively. These residues are conserved
among other family members and
species (18) (Fig. 1B). For reference
points, the N- and C-terminal
amino acids of the RUNX2 SMID
(Arg-398 and Tyr-428) were also
mutated. Co-immunoprecipitation
studies showed a decreased interac-
tion of SMAD1 with the triple
mutations of FTY residues in loop 1, while theHTYmutation in
loop 2 resulted in complete loss of interaction. The combined
mutation of both sequences (FTY-HTY) also results in com-
FIGURE1.Threeresidues intheSMIDofRUNX2definephysicalassociationwithreceptorSMADs.A, schematic
illustrationofthewild-typeRunx2proteinwithkeyregulatorydomains indicated(RHD,DNAbindingrunthomology
domain; NLS, nuclear localization signal; SMID, Smad interacting domain). SMID was established by deletion
mutagenesisandco-immunoprecipitationapproach.B, sequenceof the41aminoacids thatconstituteSMID.Based
on SMID, crystal structure residues in twopredicted fingersweremutated to alanine. Relative positions ofmutated
amino acids are indicated in bold. C, HeLa cells were transiently co-transfectedwith 5g of FLAG-tagged receptor
Smad1 andHA-taggedwild-typeormutantRunx2expressionplasmid. Cellswere treatedwith100ng/mlof recom-
binant BMP2 3 h post-transfection and harvested 24 h later. Immunoprecipitations were performed on sonicated
cell lysates using RUNX2 antibody or species-matched control IgG. Immunoprecipitates and 10%of input samples
were resolved on SDS-PAGE, and Western blots were probed with either RUNX2 antibody or FLAG antibody to
detect SMADproteins. Specific bands corresponding to RUNX2 and SMAD1 are indicated by arrowheads.
FIGURE 2. Expression and normal cellular distribution are preserved in HTY domain mutant RUNX2
protein. HeLa cells were seeded on gelatin-coated glass coverslips and transfected with 1 g of HA-tagged
wild-type or mutant Runx2 expression plasmid. Cells were processed for in situ immunofluorescence. Whole
cells were fixed in 4% formaldehyde, permeabilized, and stained with a polyclonal RUNX2 antibody followed
by anti-rabbit Alexa488 secondary antibody. A similar pattern of punctate nuclear signal is observed for all
mutant RUNX2 proteins. Nuclei are revealed by 4,6-diamidino-2-phenylindole staining (DAPI). Differential
interference contrast images represent bright field microscopy of respective cells. All magnifications are 63.
Runx2-Smad Complexes Integrate BMP2 Signals
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plete loss of the RUNX2-SMAD interaction, similar to the
391-mutant RUNX2, which is shown as negative control (Fig.
1C). In contrast, the paired mutation (R398A and Y428A) had
no effect on SMAD interaction. Expression levels of SMAD1
and mutant RUNX2 proteins are shown in input samples (Fig.
1C). RUNX2 interaction also occurs with the TGF-responsive
FLAG-SMAD3and reciprocal co-immunoprecipitation studies
using FLAG antibody (data not shown). Thus, our data show
the HTY motif in loop 2 of the NMTS (18) is required for for-
mation of a RUNX2-SMAD complex.
To further define the critical amino acids within the RUNX2
HTYmotif for SMAD interaction, we generated a panel of addi-
tional RUNX2 mutant proteins. All three residues of the HTY
motif were mutated individually and in pairs. We first con-
firmed the expression and in situ organization of the mutant
RUNX2 proteins (Fig. 2). All mutant proteins showed compa-
rable expression and a very punctate nuclear distribution pat-
tern similar to the wild-type RUNX2 protein. Thus, substitu-
tion of each HTY residue with alanine does not alter the
expression, nuclear import or cellular distribution of the
RUNX2 protein. Co-immunoprecipitation studies revealed
that physical association with SMAD1 protein is preserved
when single or pairs of residues aremutated (Fig. 3). Loss of the
RUNX2-SMAD interaction is observed only when all three
amino-acids (HTY) are mutated together, equivalent to dele-
tion of the entire C terminus domain (391) of RUNX2 (Fig. 3,
A and B). The input sample demonstrates comparable expres-
sion levels of all mutant proteins.
We further examined the consequences of HTYmutation on
in situ organization of RUNX2-SMAD complexes by confocal
microscopy. Like wild type, HTY mutant protein is trafficked
into the nucleus by the intact NLS but is severely compromised
in its ability to co-localize with Smad protein (Fig. 3C). In an
intact cell, a high degree of co-localization is observed between
wild-type RUNX2 protein and TGF-activated SMAD2 (69%)
and BMP2-responsive SMAD5 (73%) foci. In contrast HTY
mutant protein exhibits a dramatically decreased co-localiza-
tion of only 17 and 12%with SMAD2 and SMAD5, respectively.
Thus HTY mutation disrupts both biochemical and in situ
association with receptor SMADs. Taken together these find-
ings establish the HTYmotif as a minimal contact point that is
required for formation of the RUNX2-SMAD regulatory com-
plex in response to BMP/TGF signaling.
Mutations in SMID Do Not Alter RUNX2-mediated Tran-
scription, but Integration of the BMP/TGF Signal on Target
Gene Promoters Is Impaired—To understand the functional
consequences of disruption of the RUNX2-SMAD interaction,
we compared the ability of various SMIDmutants to transcrip-
tionally activate RUNX2 target gene promoters. Initially DNA
binding properties of each of the mutations of the HTY motif
were assessed with electrophoretic mobility shift assay assays
(Fig. 4A). Nuclear extracts prepared from transiently trans-
fected HeLa cells with the indicated Runx2 expression vector
were incubated with an oligonucleotide containing consensus
Runx sequences. Because HeLa cells lack endogenous RUNX2
protein, RUNX2 DNA binding of WT and mutant proteins
could be compared. All mutant RUNX2 proteins retain DNA
binding activities (Fig. 4A). Similar results were also noted with
in vitro transcribed and translated wild-type and SMIDmutant
RUNX2 proteins (data not shown). Consistent with their simi-
lar DNA binding activities, no significant difference in tran-
scriptional activation of a multimerized (6X-Runx-luciferase)
FIGURE 3. Histidine, tyrosine, and threonine are the minimal contact
points required for formation of the SMAD-Runx2 complex. A, HeLa cells
were transiently co-transfectedwith 5g each of receptor Smad 1 and either
wild-type or indicated Runx2 mutant plasmids using SuperFect transfection
reagent. Cells were cultured in the presence of 100 ng/ml of BMP2 and har-
vested 24 h later. Immunoprecipitations were performed with polyclonal
RUNX2 antibody as described under “Experimental Procedures.” HTY and
391 RUNX2 protein failed to co-immunoprecipitate SMAD1. B, summary of
RUNX2-SMAD complex formation is indicated schematically. Loss of associa-
tion is observed only for HTY mutant RUNX2 protein. C, HeLa cells were co-
transfected with 1 g of Smad2, Smad5, and wild-type or HTY mutant Runx2
expression plasmids. Cells were cultured in the presence of either 10 ng/ml
TGF or 100 ng/ml BMP2 and processed 21 h later for in situ immunofluores-
cence. Ten cells from two independent coverslips with equal expression lev-
els of both proteins were quantified for co-localizations of RUNX2 and SMAD
foci by confocal microscopy, and a representative image is shown. The num-
bers represent the degree of co-localization observed for wild-type (69 and
73%) and HTY mutant (17 and 12%) proteins, respectively.
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promoter reporter was observed
(Fig. 4B). WT and all mutant
RUNX2 proteins showed enhanced
promoter activity (3- to 3.5-fold)
when compared with empty vector
control. However, when the
RUNX2-SMAD transcriptional
activation function was examined
using a promoter that contains
DNA binding sites for both Runx
and Smad (3X-TBRE-Luc), differ-
ential responses to TGF in the
presence of SMAD2 were observed
(Fig. 4C). When compared with
WT, the HTY mutant RUNX2
showed 50–70% reduced TGF
responsiveness, whereas a complete
loss was seen for 391 RUNX2 pro-
teins. Impaired TGF responsive-
ness of HTY and 391 proteins is
consistent with loss of RUNX2-
SMAD physical association. Taken
together these data demonstrate
that mutation of the HTY motif in
RUNX2 does not change DNA
binding or transcriptional activa-
tion but selectively blocks integra-
tion of the BMP/TGF regulatory
signal for target gene expression.
Integrity of the RUNX2-SMAD
Molecular Complex Supports BMP2-
induced Commitment to the Osteo-
blast Phenotype and Osteoblast
Differentiation—Induction and
progression of osteogenesis from
mesenchymal stem cells are linked
with bone morphogenetic protein
signals. Therefore, interaction of
BMP responsive SMADs with
RUNX2 may represent a key com-
ponent of the BMP2 signal trans-
duction pathway. To test the
hypothesis that osteoblast differen-
tiation is critically dependent on the
RUNX2-SMAD molecular com-
plex, we designed a biological assay
using a previously characterized
immortalized Runx2 null cell line
(15, 27). These cells were infected
with adenovirus expressing either
wild-type or mutant RUNX2 pro-
teins and cultured for 12 days in the
presence or absence of BMP2 as
shown in Fig. 5. Comparable levels
of both wild-type and mutant
RUNX2 proteins are expressed for
an extended time sufficient to allow
cellular differentiation, then slightly
FIGURE4.MutantRUNX2proteinsexhibitnormalDNAbindingandfunctionalactivationbutnotthe integra-
tion of BMP/TGF signal. A, nuclear extracts (10 g) prepared from transfected HeLa cells with indicated Runx2
plasmids were used for electrophoretic mobility shift assay. Comparable DNA binding activities indicated by the
arrowheadarenotedforallRUNX2proteins.B,HeLacells cultured in6-welldisheswereco-transfectedwith0.4gof
pcDNA3.1 empty vector, wild-type, andmutant Runx2 plasmid and 1g of 6X-Runx-Luciferase reporter plasmids.
Cells were harvested 24 h post-transfection, and luciferase activities were determined. Pooled data from two inde-
pendent experiments (n 12) are shown. C, cells were co-transfected with 0.5 g of Smad2, 0.5 g of indicated
Runx2, 0.5 g of 3X-TBRE-Luciferase reporter plasmids, and 100 ng of Renilla luciferase construct as an internal
control. Each TGF response element in TBRE-luciferase reporter also contains an overlapping Runx binding ele-
ment. Cells were treatedwith 5 ng of TGF for 6 h prior to harvest for luciferase assays. TGF stimulated enhanced
(2- to 2.5-fold) promoter activation is lost by HTY and391 RUNX2mutant proteins.
FIGURE 5. Expression of wild-type and mutant RUNX2 proteins in reconstituted null cells is sustained
throughout the osteoblast differentiation time course.A, schematic illustration of the reconstitution biological
assay. Three days after plating, Runx2 null cells were infected with adenovirus expressing wild-type or mutant
RUNX2protein for4h.Cellswerethenculturedforadditional12days inosteo-inductivemixtureand inthepresence
andabsenceof100ng/mlBMP2.B,Runx2null cellswere infectedwithwild-type(50m.o.i.),Y428A(70m.o.i.),HTY(60
m.o.i.), and 391 (37 m.o.i.) and cultured for 12 days in 6-well dishes. Cells at indicated days were directly lysed in
platesasdescribedunder“ExperimentalProcedures.”ForcomparisonofRUNX2expression levels,equalamountsof
cell lysates were resolved on 10% SDS-PAGE forWestern blot analysis. Blots were probedwithmonoclonal RUNX2
antibody, stripped, reprobedwith LaminB antigen, and used as loading control.
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decrease by 2 weeks (Fig. 5B). Expression of the bone pheno-
typic early marker ALP during 12 days of culture in osteogenic
media was determined by mRNA levels and cytochemical
staining (Fig. 6). Runx2 null cells are incompetent to differ-
entiate in response to BMP2 alone or when infected with
control (empty vector) virus, as indicated by the lack of ALP
activity in control cells. However, reintroduction of either
wild-type RUNX2 or Y428A RUNX2 mutant protein (previ-
ously shown to reduce RUNX2 subnuclear targeting (24)) by
adenovirus infection restored the osteoblast phenotype with
nearly equivalent activity (Fig. 6B). A progressive increase in
ALP activity was observed during 12 days, which was further
enhanced from 3- to 6-fold upon BMP2 stimulation (Fig.
6A). In sharp contrast, cells reconstituted with either HTY or
391 RUNX2 mutant were devoid of ALP enzyme activity in
the absence or presence of BMP2 at any time point. These
findings are not related tomodifications in cell density nor to
the loss of protein expression, as comparable levels were
seen over 12 days (Fig. 5B, and data not shown). We do
observe a slight increase in ALP mRNA levels (2-fold) with
HTY RUNX2; however, treatment with BMP2 did not
change these levels. The negative controls (EV and RUNX2
391) had undetectable ALP mRNA levels.
These data suggest that, although
HTY mutant RUNX2 protein ex-
hibits normal DNA binding and
transcriptional activation profiles in
promoter-reporter assays, loss of
SMAD interaction considerably
decreased its capacity to induce
osteogenic differentiation, as well as
resulted in failure of integration of
the BMP2 osteogenic signal in a bio-
logical assay.
The RUNX2-SMAD Complex Is
Required for the Progression of
Osteoblast Differentiation—To
determine the function of the HTY
mutant RUNX2 protein with
respect to late stages of osteoblast
differentiation, the osteogenic
properties of the reconstituted
Runx2 null cells were examined by
monitoring expression of mid and
late osteoblastmarker genes (Fig. 7).
Histone H4 mRNA expression,
which is coupled to DNA synthesis
showed a similar profile in all treat-
ment groups with cessation of cell
growth observed after day 8 of dif-
ferentiation (data not shown).Wild-
type and the Tyr-428 mutant
RUNX2 protein showed a temporal
activation of phenotypic markers
(collagen type I, osteopontin, bone
sialoprotein, Runx2, Osterix, and
osteocalcin) to the same extent. In
contrast, this expression profile for
RUNX2 target genes is reduced to 50% with the HTY mutant,
similar to early stage marker ALP. The 391 RUNX2 mutant,
which lacks the SMID and C terminus, completely failed to
activate any RUNX2 target genes that reflect differentiation.
Thus Runx2 null cells can only fully progress through stages of
osteoblast maturation if reconstituted with RUNX2 protein
that retains a RUNX2-SMAD interaction. However, we do find
that the homeodomain proteins DLX3 and HOXA10, recently
characterized as proteins that contribute to activation of bone-
related genes for promoting osteoblast differentiation, inde-
pendent of RUNX2 (33, 34), are expressed nearly equivalently
by wild-type and all mutant RUNX2 proteins. These results
indicate their expression during osteoblast differentiation is
not dependent on RUNX2 activities (Fig. 7).
To provide evidence that the RUNX2-SMAD interaction
is essential for incorporating a regulatory signal from the
BMP2/TGF pathway for osteoblast differentiation, expres-
sion of the osteogenic marker genes was examined in
response to BMP2 (Fig. 8). A modest anti-proliferative effect
(0.35-fold decreased histone H4 expression) was observed
in the presence of BMP2 for the HTY, Y428A, and 391
mutant proteins; thus this BMP2 function is not dependent
on RUNX2-SMAD interactions. The -fold induction values
FIGURE 6. Loss of osteogenic differentiation and BMP signal integration by SMID mutant RUNX2.
A, commitment of reconstituted Runx2 null cells to osteoblast lineages was tested for 12-day time period.
Runx2 null cells cultured in 6-well dishes were infected with pre-determinedm.o.i. of Runx2 (wild-type, Y428A,
HTY, and 391) and control adenovirus. Schematic illustration of a 6-well culture dish on the left indicates
different adenovirus and their respective wells. Cells with indicated treatments and days were fixed, and
immunocytochemistry for early marker alkaline phosphatase was carried out as described under “Experimen-
tal Procedures.” Images of scanned ALP-stained plates are presented. ALP activity and BMP2 enhanced signal
were seen only inWT- and Y428A-expressing cells. B, cells infected with indicated adenoviruses were cultured
in the presence and absence of BMP2 (100 ng/ml) in osteogenicmedia and harvested at the indicated days for
total RNA isolation. Relative expression levels of the ALP early marker gene for osteoblasts weremonitored by
real-time reverse transcription-PCR analysis.
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(BMP2/Control) showed generally similar BMP responsive-
ness between WT and Y428A for bone matrix-related
RUNX2 target genes. However, BMP2 responsiveness is
compromised by Runx2 HTY mutant proteins for bone
matrix proteins, RUNX2, DLX3, and HOXA10, the three
transcription factors whose expression in mesenchymal cells
is induced by BMP2 (35, 36), further emphasizing the signif-
icance of RUNX2-SMAD-mediated BMP2 signaling. BMP2
effects of enhanced osteogenic differentiation for target gene
expression are clearly integrated by wild-type and Y428A
mutant RUNX2 proteins, which retain SMAD transduction
signaling. BMP2 mediated stimulation (2–5 fold) is seen for
collagen type I, osteopontin, BSP, osteocalcin, and Runx2.
We note that for Y428A on day 12, the BMP2 -fold stimula-
tion for Col-1 was highest in this representative study. Inte-
gration of the BMP2 signal for all marker genes was com-
pletely lost or significantly reduced in HTY and 391
RUNX2 mutants where SMAD interactions are disrupted.
The anomaly of a 3-fold increased expression of BSP by 391
on day 4 was related to extremely low transcript levels as
shown in Fig. 7.
Taken together these findings demonstrate that three resi-
dues (HTY) in RUNX2 define a critical motif for formation of
RUNX2-SMAD regulatory complex, which is essential for acti-
vation of gene networks that drive osteoblast differentiation. In
summary our results clearly establish RUNX2 as a molecular
end point that is required for execution and completion of
TGF/BMP2 signaling in osteoblasts.
FIGURE 7. Disruption of RUNX2-SMAD interaction results in altered expression of osteoblast markers genes. The osteogenic capacity of the wild-type
and mutant Runx2 proteins were tested in a reconstitution assay of Runx2/ cell line. Cells were plated in 6-well dishes, and upon confluency infected with
Runx2 adenovirus for 4 h. Cells were thenwashed and cultured for indicated days in osteogenicmedia (MEM supplementedwith 10% fetal bovine serum, 10
mM-glycerol phosphate, and 50g/ml ascorbic acid). Control and Runx2-infected cells were harvested for RNA isolation at indicated days. Real-time reverse
transcription-PCR analyses were performed to assess expression of the cell cycle, RUNX2 target, and other transcription factor genes during osteoblastic
differentiation.Data arepresentedas relative transcript normalized toglyceraldehyde-3-phosphatedehydrogenase levels in the same sample. All experiments
were performed in duplicates, and mean normalized values with standard deviation are shown.
Runx2-Smad Complexes Integrate BMP2 Signals
MARCH 28, 2008•VOLUME 283•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 8419
 at Univeristy of M
assachusetts M
edical Center/The Lam
ar Soutter Library, on Novem
ber 3, 2009
w
w
w
.jbc.org
D
ow
nloaded from
 
DISCUSSION
Our principal finding is the demonstration of a critical
requirement for BMP-induced RUNX2-SMAD interaction to
transduce the osteogenic signal that leads to osteoblast differ-
entiation. Although RUNX2 has been characterized as an
essential transcription factor for bone formation and BMP2, -4,
and -7 have been appreciated as potent osteogenicmorphogens
(37–40), the interdependency of these two factors for promot-
ing osteoblast differentiation is now established from our stud-
ies. We have demonstrated a definitive mechanism by which
BMP signaling is transduced to an osteogenic signal through
the formation of RUNX2-SMAD transcriptional regulatory
complexes. This mechanismwas characterized by site-directed
mutagenesis of Runx2, identifying a requirement for mutation
of three contiguous residues to abrogate the RUNX2-SMAD
physical and functional interaction. This HTYmutant RUNX2
was incompetent to restore osteoblast differentiation of Runx2
null cells.
The consequences of the HTY RUNX2 mutation on osteo-
blast differentiation upon reconstitution of the Runx2 null cell
line are observed to be nearly as severe as that of the RUNX2
391 mutant with deletion of the entire C terminus. The com-
parison of these two mutants in this cell model supports an
interpretation that the Runx2C knock-in mouse phenotype
lacking a mineralized skeleton can be attributed largely to the
loss of SMAD interaction with RUNX2 (17). The HTY mutant
RUNX2 mediates a 50–75% reduced activation of target gene
(ALP,COL-1,OP,BSP, andOC) expression in a cellular context,
FIGURE 8. Integration of BMP2 osteogenic signal by RUNX2 during differentiation requires RUNX2-SMAD interaction. Runx2/ cells were cultured in
6-well plates and 3 days later infected with the pre-determinedm.o.i. of indicated Runx2 adenoviruses. Cells were fed every other day with osteogenic media
in thepresenceor absenceof 100ng/ml BMP2. Cellswereharvested at the indicateddays, andRNAwas isolated. Real time-PCR for selectivemarker geneswere
carried out in duplicate, and valueswere normalized to internal glyceraldehyde-3-phosphate dehydrogenase levels in the same sample. Data are presented as
-fold induction (virus-infected BMP2-treated/virus-infected control).
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although themutants exhibit normalDNAbinding, and equally
activate a multimerized promoter. Yet, BMP2 addition fails to
enhance transcriptional activity of HTY RUNX2.
A second key finding of our studies is that RUNX2 can func-
tion in the absence of exogenously added BMP2; however,
BMP2 alone is insufficient for complete differentiation to the
osteoblast phenotype in the absence of RUNX2. This novel
finding could only have been established in an early embryonic
osteogenic lineage cell devoid of theRunx2 gene. The establish-
ment of a cell line from calvarial tissue of the E17.5 Runx2 null
mice provided us with a powerful and unbiased biological assay
system (27). Complete differentiation of our pre-osteogenic
immortalized Runx2 null cell line by BMP2 is dependent on
Runx2. These findings are similar to primary osteoblastic cells
isolated from the Runx2/ mouse (15, 26). However, one
recent report has described a fibroblastic cell line immortalized
from the Runx2 null mouse that can respond to BMP2 signal
independent of Runx2 (41). Our cell line has allowed us to per-
form reconstitution studies with wild-type andmutant RUNX2
proteins to determine the independent and convergent nature
of the RUNX2 and BMP osteogenic signals. It is interesting to
note that cellular levels of other osteogenic factors (BMP,
C/EBP, ATF4, steroid receptors, homeodomain, and Hox tran-
scription factors) that may be present in these pre-osteogenic
cells are not sufficient to mediate the BMP2 response for the
complete program of osteoblast differentiation.
Significantly, the RUNX2 HTY mutation not only disrupts
formation of the RUNX2-SMAD co-regulatory complex but is
linked to the organization of RUNX2-SMAD complexes neces-
sary for transduction of the BMP signal. RUNX2 is associated
with the nuclear scaffold by a nuclear matrix targeting signal.
Although SMADs enter the nucleus in response to a BMP
ligand, there is a requirement for further trafficking and recruit-
ment to RUNX2 foci to transduce the BMP2 signal to activation
of RUNX2 target genes (24). Formation of tissue-specific tran-
scriptional regulatory complexes involving their organization
in subnuclear specific domains is a fundamental level of control
for achieving either developmental or tissue-specific gene reg-
ulation. Although several important RUNX2 co-regulatory
proteins have now been identified that interact in the C-termi-
nal region (9, 10), the present studies firmly establish that the
osteogenic effects of BMP2 are accounted for by RUNX2-
SMAD interactions and suggest that these interactions contrib-
ute to the in vivo bone phenotypes in human and mouse.
In summary, our studies provide direct evidence that
RUNX2 does not require BMP2 for expression of osteoblast
genes, but BMP2 requires RUNX2 for induction of osteoblast
differentiation. The loss of SMAD function by the HTY muta-
tion coupled with the inability of this mutant to be organized
with co-regulatory proteins in subnuclear domains, establishes
a critical structural requirement for RUNX2-SMAD interac-
tions in RUNX2-specific subnuclear domains, as necessary for
mediating BMP/TGF signaling related to the control of osteo-
blast differentiation. BMP2, -4, and -7 have established roles in
skeletogenesis (37).We propose that the RUNX2-SMAD inter-
action is a mechanism for specification of the osteogenic activ-
ity of themulti-functional BMPmorphogens that can affect the
development of other cell phenotypes and tissues (muscle,
nerve, and skin) (42–45). Development of skeletal lineage cells
requires coordinated activity of both RUNX2 and BMP2, and,
in the absence of the RUNX2 platform, osteogenic signaling of
BMP pathways is blunted.
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